Earnings Releases·Nov 2, 2026, 4:02 PM ET

Syndax Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total revenue rose 82% year-over-year to $83.3 million, driven by 90% growth in Revuforj net revenue ($60.7 million) and 47% growth in Niktimvo net revenue ($67.4 million), while net loss narrowed to $49.4 million from $60.7 million in the prior year period.
The company raised full-year 2026 expense guidance to approximately $400 million (excluding $50 million in non-cash stock compensation) and confirmed a robust pipeline with the RAVEN trial and SNDX-4321 IND submission expected in Q4 2026.
Development of axatilimab in idiopathic pulmonary fibrosis was discontinued following the MAXPIRe Phase 2 trial's failure to meet its primary endpoint, though the drug remains a first-in-class option for chronic graft-versus-host disease.
Leadership transitioned with the appointment of Aaron A. Ondrey as CFO effective November 9, 2026, replacing Keith Goldan, while the company maintains $551.1 million in cash and investments to support its path to profitability.